Eco Animal Health gets positive opinion from EMA on Aivlosin use
The AIM-traded firm explained that mycoplasma hyopneumoniae is "the most common" primary pathogen in pig respiratory disease, and is a "key instigator" of secondary bacterial and viral pathogens.
It said its patented antimicrobial, Aivlosin, is used under veterinary prescription for the treatment of a variety of "economically important" respiratory and enteric diseases in poultry and pigs.
The European Commission was expected to issue a marketing authorisation within two months of the publication of a positive opinion, the board said.
"Aivlosin offers a safe and highly effective medication for Mycoplasma infections," said chief executive officer Marc Loomes.
"This positive opinion is significant, not only in the European Union, which has 15% of the world's pigs, but for other large international swine markets as this indication is rolled out.
"Whilst we bring forward our new product development programme, particularly around vaccines, it is important to note that Aivlosin's approved usage continues to expand across multiple treatment areas and markets."
At 1548 BST, shares in Eco Animal Health Group were up 5.32% at 208p.